Donna M. Marinucci

The Molecular Analysis for Therapy Choice (NCI-MATCH) Trial: Lessons for Genomic Trial Design

Keith T. Flaherty, Robert J. Gray, Alice P. Chen et al. · JNCI Journal of the National Cancer Institute · 2020 · 228 citations · Full text

Medicine, Molecular Medicine, Oncology +17

A randomized, phase III multicenter trial of gemcitabine in combination with carboplatin or paclitaxel versus paclitaxel plus carboplatin in patients with advanced or metastatic non-small-cell lung cancer

Joseph Treat, R Gonin, Mark A. Socinski et al. · Annals of Oncology · 2009 · 72 citations · Full text

Medicine, Oncology, Pharmacology +14

Development of Clinical Trials in a Cooperative Group Setting: The Eastern Cooperative Oncology Group

David M. Dilts, Alan Sandler, Steven K. Cheng et al. · Clinical Cancer Research · 2008 · 54 citations · Full text

Medicine, Oncology, Cancer Control +16

A randomized phase III trial of gemcitabine (G) in combination with carboplatin (C) or paclitaxel (P) versus paclitaxel plus carboplatin in advanced (Stage IIIB, IV) non-small cell lung cancer (NSCLC): Update of the Alpha Oncology trial (A1–99002L)

Joseph Treat, Chandra P. Belani, Martin J. Edelman et al. · Journal of Clinical Oncology · 2005 · 53 citations

Medicine, Oncology, Pharmacology +17

A retrospective analysis of outcomes by age in a three-arm phase III trial of gemcitabine in combination with carboplatin or paclitaxel vs. paclitaxel plus carboplatin for advanced non-small cell lung cancer

Rafat Ansari, Mark A. Socinski, Martin J. Edelman et al. · Critical Reviews in Oncology/Hematology · 2010 · 50 citations

Medicine, Oncology, Pharmacology +14